H.B. Fuller Medical Adhesive Technologies Inc. acquires Advanced Medical Solutions Group plc for GBP 659,000,000 (2026)

Deal facts

Buyer: H.B. Fuller Medical Adhesive Technologies Inc.
Target: Advanced Medical Solutions Group plc
Deal value: GBP 659,000,000
Announced: 25 June 2026
Status: Firm intention
Sector: Healthcare
Country: United Kingdom
Consideration: cash

Sources

What we know

H.B. Fuller Medical Adhesive Technologies Inc. has agreed to acquire Advanced Medical Solutions Group plc in a strategic acquisition valued at GBP 659 million. The transaction involves a full cash consideration and marks a cross-border deal where a US-based buyer acquires a UK-listed target within the healthcare sector. This firm intention was announced on 25 June 2026, establishing the commercial terms for the proposed combination of the two entities.

The deal remains in the early stages of execution as the transaction has not yet completed. No completion date has been confirmed in the available data, and the process is currently subject to the necessary regulatory approvals required for such a significant cross-border acquisition. The parties have not disclosed specific timing for the final closing beyond the initial announcement date. This summary reflects the current status of the agreement without speculation on future operational integration or strategic outcomes. The transaction is subject to regulatory approval.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

25 Jun 2026Firm intention
Recommended Cash Acquisition
FOR IMMEDIATE RELEASE 25 June 2026 RECOMMENDED CASH ACQUISITION OF ADVANCED MEDICAL SOLUTIONS GROUP PLC BY H.B. FULLER MEDICAL ADHESIVE TECHNOLOGIES INC., A WHOLLY-OWNED SUBSIDIARY OF H.B. FULLER COMPANY to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006 1. Summary Further to the announcement made by Advanced Medic
LSE RNS

OpinionExit Mode editorial

We see a clear signal in the cross-border move by H.B. Fuller Medical Adhesive Technologies Inc. to acquire Advanced Medical Solutions Group plc for 659 million GBP. This is a strategic acquisition announced on 25 June 2026, where a US buyer targets a UK healthcare firm with a firm intention to proceed. The all-cash consideration removes the immediate equity risk for the target shareholders, yet it places the entire burden of funding and execution on the buyer. For the SME founder reading this, the structure is straightforward but the regulatory path is not. A transaction of this size between a US entity and a UK public company will inevitably trigger scrutiny from the Competition and Markets Authority.

The deal mechanics here are defined by the cash nature of the offer and the public status of the target. Because Advanced Medical Solutions Group plc is listed, the buyer must navigate the City Code on Takeovers and Mergers alongside standard competition law reviews. The CMA has jurisdiction to block deals that may substantially lessen competition, and given the specific niche of medical adhesives, the regulators will examine market concentration closely. The firm intention status means the buyer has committed to making a formal offer, but completion remains conditional on regulatory clearance. This is a standard but critical hurdle that can delay or derail even the most well-funded transactions. The absence of an earn-out or share consideration suggests the buyer values certainty over future performance alignment, which is a significant negotiating stance for the target board.

Our view is that the speed of the deal will depend entirely on how well the parties prepare their competition case. The buyer cannot assume the 659 million GBP price tag guarantees a smooth passage through the UK regulatory system. The CMA review process is rigorous, and any indication of anti-competitive effects in the medical device sector will lead to an in-depth investigation. This is not a matter of if, but when and how long the review takes. Founders must understand that a cash offer does not mean a guaranteed close if the regulator raises substantive concerns. The risk of a prolonged review period can strain the target company's operations and management focus.

The specific action for any founder preparing for a sale this week is to map your customer concentration and market share data against the relevant antitrust thresholds before you sign anything. Do not wait for the buyer to ask for this information during due diligence. Prepare a clear narrative on why your acquisition will not reduce competition in the medical adhesives market, as this will be the first question regulators ask. Having this analysis ready will demonstrate commercial maturity and can significantly shorten the regulatory timeline.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from H.B. Fuller Medical Adhesive Technologies Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

11 August 2026ClearedHealthcare

Dolby Medical Home Respiratory Care Limited (Vivisol) to acquire Air Liquide Healthcare Limited’s home oxygen services business

Dolby Medical Home Respiratory Care Limited, trading as Vivisol, has agreed to acquire the home oxygen services business of Air Liquide Healthcare Limited in a strategic…

Buyer: Dolby Medical Home Respiratory Care Limited (Vivisol)
Target: Air Liquide Healthcare Limited’s home oxygen services business
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

10 August 2026Firm intentionHealthcare

RSLGH, LLC to acquire RYTHM, Inc.

RSLGH, LLC has agreed to acquire RYTHM, Inc., a healthcare company based in the United States, in a strategic acquisition valued at $109.5 million. The transaction invol…

Buyer: RSLGH, LLC
Target: RYTHM, Inc.
Deal value: USD 109,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

5 August 2026CompletedHealthcare

Ensysce Biosciences, Inc. to acquire Cy Biopharma, Inc.

Ensysce Biosciences, Inc. has agreed to acquire Cy Biopharma, Inc. in a strategic acquisition within the healthcare sector. The transaction was announced on 5 August 202…

Buyer: Ensysce Biosciences, Inc.
Target: Cy Biopharma, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

31 July 2026Firm intentionHealthcare

Profusa, Inc. to acquire G3 Vision Labs Inc.

Profusa, Inc. has agreed to acquire G3 Vision Labs Inc. in a strategic acquisition within the healthcare sector. The transaction involves the exchange of shares as the p…

Buyer: Profusa, Inc.
Target: G3 Vision Labs Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history

H.B. Fuller Medical Adhesive Technologies Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive